IGHE and cancer: Preliminary data from the MOv18 IgE trial have shown that an IgE can safely be administered systemically in patients with cancer, whilst mitigating the risk of the most common perceived toxicity risk for IgE immunotherapy, systemic anaphylaxis [114].